E17   |  19 min   |   Latest   |  Publication Source    Podcast based on: Das S, Samaddar S. Recent Advances in the Clinical Translation of Small-Cell Lung Cancer Therapeutics. Cancers. 2025; 17(2):255. https://doi.org/10.3390/cancers17020255Type: Review  |  Publication date: Jan 14, 2025 Summary: This research review comprehensively examines small-cell lung cancer (SCLC), a highly aggressive and often fatal lung cancer. It details SCLC's cellular origins, neuroendocrine characteristics, and diverse subtypes driven by distinct transcriptional regulators. The review also explores the mechanisms of chemoresistance, focusing on DNA damage response pathways, cancer stem cells, and epigenetic reprogramming. Finally, it summarises recent advancements and ongoing clinical trials investigating novel targeted therapies, including immune checkpoint inhibitors, topoisomerase inhibitors, and agents targeting DLL3, HDACs, and PARP. Keywords: small-cell lung cancer; molecular subtypes; chemotherapy; resistance Disclaimer:This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. While efforts are made to ensure accuracy, this podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.